An interventional study of Sleeve Gastrectomy With Omentopexy and Sleeve Gastrectomy Without Omentopexy in Omentopexy, Sleeve Gastrectomy and Gastroesophageal Reflux Disease, sponsored by China-Japan Friendship Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by China-Japan Friendship Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Gastroesophageal Reflux with a site in China — 16 open to participants now, 17 under way, none of them phase 3. Gastroesophageal Reflux · China.
Among the 56 studies in Gastroesophageal Reflux with a site in China, this one is the 17th largest by planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2026, is one of 24 with no phase, reaches primary completion later than 12 of the 16 other live ones, and was the 56th registered.
1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →16 of the 56 studies in Gastroesophageal Reflux with a site in China are open now. Recruiting first, the newest first:
Xinghua Liu · Sites in China
Ages 18–65
Beijing Friendship Hospital · Sites in China
Ages 18–90
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Shanghai Hutchison Pharmaceuticals Limited · Sites in China
Ages 18–75
Nanchong Central Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 7 · Phase 4 2
First in 2003; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 68 across 800 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 90 across the 39 interventional studies, 1,625 across the 17 observational. Of the 24 that completed or were terminated, 5 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 56 have an industry lead sponsor. The 10 most frequent:
China-Japan Friendship Hospital is the lead sponsor of 179 studies on the registry; 112 are open to participants now.
China-Japan Friendship Hospital has 2 studies filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
5 of the studies in Gastroesophageal Reflux with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07749989Beijing Friendship HospitalA Retrospective Analysis of Patients With Gastroesophageal Reflux Disease Based on a Prospective Clinical Dataset | 2027-04 |
| NCT07943611Nanchong Central HospitalLaparoscopic Fundoplication With or Without Fixation to the Diaphragm for Gastroesophageal Reflux Disease or Hiatal Hernia | 2027-06-30 |
| NCT06755671Shanghai Hutchison Pharmaceuticals LimitedA Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms | 2027-06-30 |
| NCT07795645Beijing Friendship HospitalValidating a Medical AI Fine-Tuning Platform for Major Diseases | 2027-08-31 |
| NCT07854613China-Japan Friendship HospitalDe Novo Gastroesophageal Reflux Disease After Sleeve Gastrectomy With and Without Omentopexy | 2027-10-15 |
Add all 5 to your calendar (.ics) → With an account.
Among the 56 studies in Gastroesophageal Reflux with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare the effects of sleeve gastrectomy with and without omentopexy on gastroesophageal reflux disease (GERD) in patients with obesity. The main question it aims to answer is:
Does the addition of omentopexy to sleeve gastrectomy reduce the incidence of postoperative GERD compared with sleeve gastrectomy alone, as measured by the proportion of participants with a postoperative GERD-Q score ≥8?
Researchers will compare sleeve gastrectomy with omentopexy to sleeve gastrectomy without omentopexy to determine whether omentopexy reduces the incidence of postoperative GERD.
Participants will:
Undergo sleeve gastrectomy with or without omentopexy according to their randomized treatment assignment.
Complete the GERD-Q questionnaire after surgery to assess gastroesophageal reflux symptoms.
Attend postoperative follow-up visits for assessment of GERD and other clinical outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Preoperative gastroesophageal reflux disease (GERD), defined by any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo sleeve gastrectomy with omentopexy according to the study protocol.
Procedure: Sleeve Gastrectomy With Omentopexy
Participants will undergo sleeve gastrectomy without omentopexy according to the study protocol.
Procedure: Sleeve Gastrectomy Without Omentopexy
Participants assigned to this intervention will undergo sleeve gastrectomy with omentopexy according to the study protocol. Omentopexy will be performed by fixation of the gastric sleeve to the adjacent omental tissue following sleeve gastrectomy.
Participants assigned to this intervention will undergo sleeve gastrectomy without omentopexy according to the study protocol.
Prevalence of de novo postoperative gastroesophageal reflux disease (GERD)
The proportion of participants with a postoperative GERD-Q score of 8 or higher.
Time frame: 12 months after surgery
GERD severity assessed by the GERD-HRQL score
The severity of gastroesophageal reflux disease will be assessed using the GERD-Health Related Quality of Life (GERD-HRQL) questionnaire. The highest score was 75 and the lowest score was 0. Higher scores indicate greater severity of GERD symptoms.
Time frame: 12 months after surgery
Endoscopic findings of gastroesophageal reflux disease
Postoperative upper gastrointestinal endoscopy will be performed to assess endoscopic evidence of gastroesophageal reflux disease, including reflux esophagitis and other relevant findings. The presence or absence of endoscopic evidence of gastroesophageal reflux disease will be recorded.
Time frame: 12 months after surgery
Incidence of hiatal hernia
The presence of hiatal hernia will be assessed by postoperative upper gastrointestinal endoscopy. The presence and size of hiatal hernia will be recorded based on postoperative upper gastrointestinal endoscopy.
Time frame: 12 months after surgery
Severity of reflux esophagitis according to the Los Angeles classification
The severity of reflux esophagitis will be assessed by postoperative upper gastrointestinal endoscopy using the Los Angeles classification (Grades A, B, C, and D).
Time frame: 12 months after surgery
Postoperative proton pump inhibitor use
The use of proton pump inhibitors (PPIs) for the management of postoperative GERD will be recorded, including the type of PPI, dosage, frequency of administration, and treatment duration.
Time frame: 12 months after surgery
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
Of 194 non-industry interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 68. This study's planned 12 months is below that.
Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China-Japan Friendship Hospital →